Sanofi unveils EUROAPI as name of new API company The global pharmaceutical firm expects big things from its newly formed active pharmaceutical ingredients company, to be led by new CEO Karl Rotthier.
Sanofi has unveiled EUROAPI as the name of its new European active pharmaceutical ingredients (API) company. Additionally, the firm has appointed Karl Rotthier as its future CEO.
According to Sanofi, the new company stands to be the largest API organization in the European Union, with projected sales of approximately €1b ($1.2b USD) by 2022. Additionally, the parent company anticipates EUROAPI will rank first on the continent in small-molecule APIs and second in the global API market.
Fight against pharma counterfeiting must go deeper: TruTag A leader from the anti-counterfeit solutions firm says that while packaging-level efforts may have an effect, on-dose technology is worth a closer look.
Pharmaceutical counterfeiting is a serious, pervasive threat; according to the World Health Organization, fake drugs drain the global economy of as much as $200b in lost profits annually. Considering the risk to patient safety, it is an issue with potentially deadly consequences.
Michael Bartholomeusz, TruTag CEO, told Outsourcing-Pharma that the pharmaceutical industry is highly focused on finding ways to defeat counterfeiters.
“
Pharmaceutical companies and the industry at large are acutely aware of the problem of counterfeit and diversion and have expended enormous effort, resources and money around grappling with the problem,” he said. “
Authorities discovered the fake Pfizer erectile-dysfunction tablets in one of three cargo containers full of fraudulent goods, recently arrived from China.